Advocates Yael Baratz, Ilan Gerzi, Benjamin Waltuch and Chen Moshe represented OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, in listing all of the shares of OPKO on the Tel-Aviv Stock Exchange (“TASE”) under the ticker symbol OPK. OPKO’s common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.
Based on OPKO’s $2.7 Billion market capitalization, OPKO expects its shares to be included in the TA-25 Index (TA-25) which is the TASE flagship index which tracks the share prices of the 25 companies with the highest market capitalization on the exchange.
The listing comes prior to the completion of the OPKO’s pending acquisition of PROLOR Biotech, Inc., a biopharmaceutical company based in Nes Ziona, Israel in which Advocate Yael Baratz represented OPKO in its $480 million stock for stock acquisition of PROLOR by OPKO.
The transaction is noteworthy because it is the first stock for stock acquisition of an Israeli public company since 2006 that required a prospectus in Israel. This is also the first dual listing in many years where the dual listed entity is expected to be included in the TA-25. Finally, OPKO will become the second foreign company currently listed in the TA-25.
